Alyftrek 4-20-50 MG tablet 21S
Ended Awarded Last action
- Contract number
- SPE2DR26FQWK3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $64,275
Award facts
- Contract value 100% obligated
- $64,275.09 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $64,275.09 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of ALYFTREK 4-20-50 MG tablets (21-count packages). The contract is a firm fixed-price delivery order with an ultimate completion date of January 12, 2026, and carries no set-aside designation, indicating the award was made through open competition. This delivery order is issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to ensure stable, efficient pharmaceutical supply chains for Department of Defense healthcare operations globally.
DMS Pharmaceutical Group has demonstrated substantial contracting capability as a critical supplier within the federal pharmaceutical supply chain, with recent delivery orders spanning oncology treatments, biologics, vaccines, and routine pharmaceuticals. The company's prime vendor contract, valued at $499,999,999 and effective through December 31, 2036, positions it as one of multiple regional prime vendor contractors authorized to supply the comprehensive range of pharmaceutical products necessary to support military healthcare facilities worldwide. The January 2026 ALYFTREK award exemplifies the recurring delivery order activity under this broader prime vendor framework, enabling DLA to procure specialized pharmaceutical products to meet ongoing Department of Defense medical supply requirements.
Quick answers
Who was awarded contract SPE2DR26FQWK3?
SPE2DR26FQWK3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 9, 2026.
How much is contract SPE2DR26FQWK3 worth?
The government has obligated $64,275 on SPE2DR26FQWK3.
Is contract SPE2DR26FQWK3 an order under another contract?
Yes. SPE2DR26FQWK3 is a delivery order under SPE2DR25D9353, an indefinite delivery contract.
Was contract SPE2DR26FQWK3 competed?
The extent of competition for SPE2DR26FQWK3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award